RK

Ramesh Kishanrao Jadhav

Active Director Designated Partner DIN 11245042
DIN 11245042 First appointment Aug 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Aug 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Ramesh Kishanrao Jadhav

Data last updated:

Ramesh Kishanrao Jadhav is a Designated Partner at Glomerulus Pharma Llp (since 2025) and Partner at Nu Kidney Superspeciality Llp (since 2025).

DIN 11245042
Primary Designation Designated Partner
First Appointment 04 Aug 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner18 Aug 20252025Active
Partner04 Aug 20252025Active

Board colleagues of Ramesh Kishanrao Jadhav

Directorship timeline

Open interactive timeline →
Glomerulus Pharma Llp
Nu Kidney Superspeciality Llp
Premium access

Shareholding and investment profile for Ramesh Kishanrao Jadhav

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ramesh Kishanrao Jadhav

Ramesh Kishanrao Jadhav currently holds 2 directorships: Glomerulus Pharma Llp (Designated Partner, since 18 Aug 2025); Nu Kidney Superspeciality Llp (Partner, since 04 Aug 2025).

Ramesh Kishanrao Jadhav was first appointed on 04 Aug 2025 as Partner at Nu Kidney Superspeciality Llp.

The current boards of Ramesh Kishanrao Jadhav's companies include Bapu Ramrao Chege (Glomerulus Pharma Llp), Mahesh Shinde (Glomerulus Pharma Llp), Naser Nazeer Patel (Glomerulus Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available